LiiRA stands for lipids, inflammation, and cardiovascular risk in rheumatoid arthritis (RA). For someone with RA, the risk of heart disease is 2x higher compared to someone from the general population. Chronic inflammation is considered a major driver for the elevated heart disease risk. The objective of LiiRA is to study the link between inflammation, cholesterol and heart disease. Data from this study will help us identify ways to reduce the risk of heart disease for patients with RA. This study is funded by the National Institutes of Health (NIH).
You can help us to understand how inflammation leads to a higher risk of heart disease in rheumatoid arthritis (RA). Ultimately, information from this study will lead to better strategies to prevent and treat heart disease. You will be reimbursed for your time and participation. If you are starting on Cimzia, an approved RA medication, you will receive the medication for six months at no cost to you.
Are you eligible?
We have completed enrollment of the main LiiRA study in the spring of 2022. We are now performing an extension study and inviting back former LiiRA participants.